Dr. George Rajan Simon, MD

Dr. Simon practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Simon's NPI, 1164438768, was assigned on August 1, 2006. Dr. Simon graduated from Christian Medical College Ludhiana in 1986. Dr. Simon holds Florida license ME83970.

Dr. Simon's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Simon's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is AdventHealth Medical Group. Dmand AI also links Dr. Simon to 2 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Simon practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Simon's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Simon is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Simon's licenses on file in 8 states: Florida, Ohio, Oklahoma, Texas, South Carolina, Pennsylvania, Colorado and Arizona.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Simon treats.

CMS data shows 131 Medicare services from Dr. Simon across 3 procedure codes in 2024, all of them office visits, for 61 Medicare patients. Medicare paid $14,424 for them.

CMS counts 61 Medicare patients who saw Dr. Simon in 2024. The largest group is 75 to 84, with 27 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 3.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Simon's median patient age at 74, with 0% women.

In 2024, Dr. Simon wrote 142 Medicare Part D claims for 29 patients. 41% of them were for generic drugs. CMS names the drug for 74 of them, across 4 drugs with 11 or more claims each, at $714,015 in total drug cost. In 2023, CMS named 99 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Simon for performance year 2024, reported as part of a group.

Dmand AI links 93 papers to Dr. Simon, published from 2005 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Simon has published most often in J Thorac Oncol. Dr. Simon's most frequent co-authors are Alberto A. Chiappori, MD, Scott Joseph Antonia, MD and Eric Haura, MD.

Dmand AI links Dr. Simon to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Lung Neoplasms. Medical University of South Carolina sponsors the most, 2.

CMS Open Payments shows 223 general payments to Dr. Simon from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 64% of the total. AstraZeneca Pharmaceuticals LP paid the most, $46,146.

Dmand AI lists 4 awards for Dr. Simon, most recently America's Top Doctors in 2014.

Dr. Simon graduated from Christian Medical College Ludhiana in 1986. Dr. Simon is a member of ACP and ASCO.

Dr. Simon is in network with 11 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Humana. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.